Lenacapavir: A Landmark in HIV Prevention

The prestigious journal 'Science' has recognized Lenacapavir, an HIV prevention drug by Gilead, as the breakthrough of the year. This innovative medication offers six months of protection with a single injection, providing a significant advancement over daily tablets like Truvada.

With around 40 million people living with HIV globally, particularly in Africa, this development holds immense promise. Past milestones in HIV research include the introduction of protease inhibitors and the HPTN 052 study, both recognized by 'Science' for reducing HIV transmission risks.

Gilead plans to make Lenacapavir accessible in various countries, including less affluent regions, marking a crucial step towards global HIV prevention. The half-yearly dosage not only simplifies treatment but also enhances patient compliance, potentially transforming the landscape of HIV management.